Canadian Collaborative Research Network
Avatar

DELIVER Trial: Does Dapagliflozin Improve Outcomes in HFpEF?

By Canadian Collaborative Research Network FEATURING Milan Gupta
By Canadian Collaborative Research Network FEATURING Milan Gupta
202 views
September 28, 2022
1 Comment
Login to view comments. Click here to Login

Featured Video

15:01
Lilly Diabetes

Discover the MOA of an Incretin Medication for T2D

Featured Video

46:20
Lilly Diabetes

A Journey Through Clinical Efficacy and Safety Data Comparing Two In…

Feat. S. Shadid

Related Content

AUTOPLAY
Medical College of Georgia - Augusta University

Cardiovascular Summit at Kiawah 2024

Thu, Jul 18, 2024
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
29:08
Scripps Health

Case Presentation: Complex PCI with IABP

Feat. R. Khedraki, T. Heywood, R. Mohan, A. Srivastava
17:08
CVRx | Barostim

Integrating Barostim into a Comprehensive Heart Failure Program ISHL…

Feat. D. Yaranov, P. Patel, R. Gupta, J. Schmitto, E. Chung
35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
17:22
Samuel Sherratt

Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Has High Membrane Affi…

17:29
UCLA Health

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

Feat. D. Vucicevic
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
12:30
Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg
22:49
Right Care Initiative

The Dilemma of Broken Heart Takotsubo Syndrome: Why Is It More Preva…

Feat. N. Merz
34:18
Scripps Health

Cancer Survivorship: How To Monitor for Cardiac Disease Following Tr…

Feat. A. Kuo